http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013110064-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_468ba69b8e2068e9319b9942dcc081b3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0208 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0291 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-472 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f841bf7a40550fe0ef16268c0870ef3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2482c6fc8f375eaf1bb169772a4ce11c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ba0f46b2e8ffc1742e2df0fd2efef3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_574835f68ca16c538dd0edd8ffe60b71 |
| publicationDate | 2014-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2013110064-A9 |
| titleOfInvention | Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen |
| abstract | Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health. |
| priorityDate | 2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.